metaPreg - Trazodone during pregnancy

Trazodone updated on 10-20-2025

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	2.39 [0.74, 7.73]	26%	4 studies	53,288	73	not evaluable	ROB	-
Major congenital malformations	2.39 [0.74, 7.73]	26%	4 studies	53,288	73	not evaluable	ROB	-
Cleft lip with or without cleft palate	-	-	0 study					-
Cleft palate	-	-	0 study					-
Oro-facial clefts	-	-	0 study					-
1 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
1 non statistically significant endpoints reported in only one study
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
2 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
1 non statistically significant endpoints reported in only one study
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Early intrauterine deaths (< 22 weeks) / Spontaneous abortions	19.92 [1.21, 328.36]	0%	2 studies	24	2	not evaluable	ROB	39.33 [1.71; .]
1 non statistically significant endpoints reported in only one study